In 2014, MAPS spun out a separate division to immediate investigate and get ready for an eventual FDA application, which it submitted at the end of past year. In early 2024, that offshoot was renamed Lykos Therapeutics.Pseudohallucinations: it doesn't lead to hallucinations for every se but produces illusions by altering the senses (all five senses